Help your customers to kick the habit for good with Nicotinell
NRT allows patients to decrease their therapeutic nicotine intake, as both the physical and behavioural dependency is reduced2-4
The Irish Health Service Executive recommends the Quit plan including sessions at stop smoking clinics and the use of smoking cessation aids including NRT to help double patients’ chance of success.5
How NRT works
Many smokers trying to quit experience withdrawal symptoms and cravings that may be hard to overcome with willpower alone.
NRT products deliver lower levels of therapeutic nicotine without the 7000 chemicals found in tobacco smoke.
- Approximately 70-90% of smokers say that withdrawal symptoms and cravings are the reason they do not quit smoking. Nicotine replacement therapy (NRT) can help relieve physical withdrawal symptoms.7
- NRT addresses your customers’ physical need to smoke using consistent, controlled therapeutic nicotine to wean them down gradually.8-10
- By reducing the physical symptoms from smoking cessation, NRT enables the customer to focus more on the emotional aspect of quitting.7
- NRT helps manage withdrawal symptoms, which manifest within the first 1-2 days, peak within the first week and gradually dissipate over 3-4 weeks.11
- Cravings are often psychologically motivated and can last for months. The use of behavioural programmes in conjunction with NRT can improve success.12
Nicotinell Medicated Chewing Gum
Face on-the-go craving relief.
Nicotinell gum is available in two different flavours (mint or fruit) to satisfy varying tastes. Easy to chew with a crispy coating just like normal gum.
Available in 2 mg and 4 mg, in a variety of pack sizes to support customer needs: 24 or 96 pieces.
Nicotinell Compressed Lozenge
Starts to work in minutes; provides discreet, effective craving relief.
Nicotinell lozenges help customers stop smoking with a fresh, minty taste. Customers can use the lozenges discreetly to help them stop smoking at work or on other occasions where they cannot chew gum.
Available in a variety of pack sizes in 1mg and 2mg strength to support customer needs: 36, 96 and 144 lozenges.
Nicotinell 24 Hour Patch
24 hour craving control.
Nicotinell patches contain enough nicotine protection for 24 hours when customers stop smoking.
By using the patches for 24 hours, customers will have nicotine in their blood when they wake up, so they’ll be ready to face the morning cravings more easily.
Nicotinell patches are available in three strengths: 7 mg, 14 mg and 21 mg in packs of 7 patches.
Nicotinell® Cool Mint 2mg/4mg medicated chewing gum (nicotine). Nicotinell® Fruit 2mg/4mg medicated chewing gum (nicotine)
Please refer to Summary of Product Characteristics for full prescribing information.
Presentation: Mint or Fruit flavoured chewing gum containing 2 mg and 4 mg nicotine. Indications: For relief of nicotine withdrawal symptoms as an aid to smoking cessation. Dosage and administration: Stop smoking completely during treatment. Adults: Chew one piece of gum slowly. Normally 8 to 12 pieces per day, up to a maximum of 24 pieces of 2 mg gum per day or 15 pieces of 4 mg gum per day. After 3 months, gradually cut down the gum usage. The higher strength gum is for those with a strong nicotine dependency. Children and adolescents (< 18 years): To be used only on medical advice. Contraindications: Hypersensitivity to any ingredient, non-smokers. Precautions: Patients with unstable cardiovascular disease, haemodynamically unstable, hypertension, stable angina pectoris, occlusive peripheral arterial disease, heart failure, diabetes mellitus, hyperthyroidism, phaeochromocytoma, renal or hepatic impairment, GI disease and seizures should seek medical supervision. Patients with fructose intolerance should not take this medicine. Stopping smoking may alter the metabolism of certain drugs. Dispose of gum with care. Consider other forms of NRT if people with jaw bone problems or denture wearers have difficulty chewing as it may stick to the dentures. Fertility, pregnancy and lactation: To be used only on medical advice. Side effects: Most side effects reported in first 3 to 4 weeks. Include: insomnia, dizziness, headache, hiccups, gastric symptoms, increased salivation, stomatitis, sore mouth or throat, jaw muscle ache, diarrhoea, dry mouth, constipation, pharyngitis, palpitations, erythema, urticaria, atrial arrhythmia, hypersensitivity, angioneurotic oedema, anaphylactic reactions. Reported dizziness, headache, cough, cold sores and insomnia may be due to nicotine withdrawal symptoms. Non dose - dependent reactions reported: jaw muscle ache, erythema, urticaria, hypersensitivity, angioneurotic oedema, anaphylactic reactions. Legal category: Supply through general sale. PA Nos: PA 678/125/1-2; PA 678/124/1-2. PA Holder: GlaxoSmithKline Consumer Healthcare (Ireland) Limited, 12 Riverwalk, CityWest Business Campus, Dublin 24, Ireland. Further information is available on request. Date of preparation: 01st June 2021. Contains nicotine. Stop smoking aid. Requires willpower. Always read the label/leaflet.
Please consult the Summary of Product Characteristics for full product information. Nicotinell Mint 1mg and 2mg compressed lozenge (nicotine) Presentation: Mint flavoured lozenges containing 1mg or 2mg nicotine. Indications: For relief of nicotine withdrawal symptoms as an aid to smoking cessation or temporary smoking reduction in those wanting to quit. Dosage and administration: Adults: Smoking cessation: Stop smoking completely. Suck one lozenge slowly. Normally, 8-12 lozenges per day. Max daily dose: 24x1mg lozenges or 15x2mg lozenge. Do not use more than 1 lozenge per hour. After 3 months, gradually cut down the usage of lozenges. The higher strength, 2mg lozenge is for those with a strong nicotine dependency. Smoking reduction: use to prolong smoke-free intervals to reduce smoking. Start quit attempt once ready but no later than 4 months after treatment starts. Gradually reduce lozenge number. If a cigarette reduction of 50 % per day is not achieved after 6 weeks, or quit attempt not made within 6 months of starting treatment seek medical advice. Not generally recommended for regular use beyond 6 months. Combination treatment: For when treatment fails with lozenge alone, 1mg lozenge and patch used together for those smoking >20 cigarettes a day, recommended to seek HCP advice. 2mg lozenge not licensed for combination therapy. Start with one patch 21 mg/24 hours plus 1mg lozenge (generally 5-6 pieces per day). Max 15 lozenges a day. Treat for 6-12 weeks, then gradually reduce nicotine dose by either 1) reducing patch strength sequentially at 3-6 weeks intervals, then gradually reducing number of lozenges. OR 2) discontinuing use of patches and gradually reducing number of lozenges. Alternate patch application site to avoid skin irritation. Max treatment duration is 9 months. Paediatric population: Not to be used by children under 12 years. Not to be used by adolescents 12-17 years of age without prescription from a healthcare professional. Contraindications: Hypersensitivity to ingredients, non-smokers. Warnings and Precautions: Lozenge may be considered under close medical supervision, where non-pharmacological methods fail in dependent smokers with a recent myocardial infarction, unstable or worsening angina including Prinzmetal’s angina, severe cardiac arrhythmias, uncontrolled hypertension or recent cerebrovascular accident. Use with caution in patients with hypertension, stable angina pectoris, cerebrovascular disease, occlusive peripheral arterial disease, heart failure, diabetes mellitus, hyperthyroidism or pheochromocytoma, severe hepatic/renal impairment or phenylketonuria, history of epilepsy or those taking anti-convulsant therapy. Swallowed nicotine may exacerbate symptoms in subjects suffering from active oesophagitis, oral and pharyngeal inflammation, gastritis or peptic ulcer. Do not use in patients with rare hereditary conditions of fructose intolerance. Pregnancy/breast-feeding/fertility: Use under medical supervision. Side effects: Very Common: Nausea. Common: insomnia, dizziness, headache, flatulence, hiccups, gastritis, dry mouth, stomatitis, abdominal pain, upper diarrhoea, constipation, pharyngitis, cough and pharyngolaryngeal pain. Uncommon: palpitations. Rare: atrial arrhythmia, hypersensitivity, angioneurotic oedema and anaphylactic reactions. Legal category: Supply through general sale PA Nos: PA 678/123/4-5 PA Holder: GlaxoSmithKline Consumer Healthcare (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland. Date of preparation: October 2020. Further information is available on request. Contains nicotine. Always read the label/leaflet.
Nicotinell TTS 10, 20, 30 (Nicotine). Presentations: Transdermal patch containing nicotine, available in three sizes (30, 20 and 10cm²) releasing 21mg, 14mg and 7mg of nicotine respectively over 24 hours. Indications: Treatment of nicotine dependence, as an aid to smoking cessation. Dosage and administration: Stop smoking completely when starting treatment. For those smoking 20 or more cigarettes a day Nicotinell TTS30 (Step 1) once daily. Those smoking less should start with Nicotinell TTS20 (Step 2) once daily. Different strength patches permit a stepwise reduction in nicotine dose over treatment periods of 3-4 weeks with each strength patch. Maximum recommended treatment period three months (but if abstinence not achieved after three month period, further treatment may be recommended following a re-evaluation of the patient’s motivation by a clinician). Children and young adults: To be used in people under 18 years only on medical advice. Contra-indications: Known hypersensitivity to nicotine or any of the excipients. Precautions: Use with caution in patients with: cardiovascular disease, history of seizure or those taking anti-convulsant therapy, diabetes mellitus, severe renal and/or hepatic impairment, active oesophagitis, oral and pharyngeal inflammation, gastritis, gastric/peptic ulcer. Discontinue use if a severe or persistent skin reaction occurs. Nicotinell TTS contains aluminium and should be removed prior to undergoing defibrillation, MRI or cardioversion procedures. Keep out of the reach and sight of children at all times due to potential poisoning risk. Pregnancy & lactation: To be used only on medical advice. Side effects: Certain symptoms such as depression, irritability, nervousness, restlessness, mood lability, anxiety, drowsiness, impaired concentration and insomnia may be related to withdrawal symptoms associated with smoking cessation. Quitting smoking by any means can lead to asthenia, headache, dizziness, coughing or influenza-like illness. Very common: insomnia, abnormal dreams, nausea, vomiting, application site reactions. Common: agitation, anxiety, nervousness, tremor, palpitations, cough, pharyngitis, dyspnoea, abdominal pain, upper dyspepsia, diarrhoea, dry mouth, constipation, increased sweating, myalgia, application site pain, asthenia, fatigue. Uncommon: hypersensitivity, disturbance in attention, somnolence, affect lability, irritability, depressed mood and confusional state, paraesthesia, dysgeusia, blurred vision, tachycardia, flatulence, hyperhidrosis, arthralgia, malaise, influenza type illness, asthenic conditions, pain and discomfort. Rare: dyspnoea, arrhythmia. Very Rare: anaphylactic reactions, allergic dermatitis, contact dermatitis, photosensitivity. Frequency not known: allergic reactions such as urticaria, rash and pruritus; angioedema and anaphylactoid reaction. PA Number: PA 678/123/001 – 002 – 003. Supply classification: Product not subject to medical prescription. PA holder: GlaxoSmithKline Consumer Healthcare (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland. Further information is available on request. Date of preparation: December 2019.